Access the video webcast here HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here . The presentation, featuring Walter Klemp, Chairman and Chief Executive Officer of Moleculin, provides an overview of the Company as well as recent corporate and clinical developments. Th

Fireside chat featuring Bob Jahr, Chief Executive Officer, and H.C. Wainwright Managing Director & Senior Biotechnology Equity Research Analyst Access the video webcast here ISELIN, N.J., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that its pre-recorded fireside chat from the H

Kensington, MD, USA and Munich/Martinsried, Germany, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Kensington, MD, USA, and Munich/Martinsried, Germany, September 11 , 2026 – Galimedix Therapeutics, Inc. (“Galimedix”), a Phase 2 clinical-stage biotechnology company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases, today announced that functional feasibility data from its Phase 2 eDREAM study evaluating GAL-1

MELBOURNE, Australia & SAN DIEGO--(BUSINESS WIRE)--Nutromics is building a wearable lab-on-a-patch™ for continuous molecular monitoring. Today the company has announced that the FDA has granted Breakthrough Device Designation (BDD) for its first product in development - a wearable for vancomycin therapeutic drug monitoring. The FDA’s Breakthrough Device Program is designed to bring promising new medical technologies to patients sooner by accelerating development and regulatory engagement and rev

iStock, z_wei The polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the FDA’s approval last month for Mimrylo. While recent data from Disc Medicine’s investigational antibody appear competitive in the polycythemia vera space, analysts believe Silence Therapeutics continues to be the player to beat in the race to bring the next PV therapy to market. Disc’s a

Scientists have created an ultra-small nanolaser that could eventually allow microchips to transmit information with light instead of electricity, potentially making computers faster while cutting energy use roughly in half. Thousands of the lasers could fit on a single chip, opening possibilities for more efficient data centers, smartphones, and advanced medical sensors.The development of a nanolaser could mark an early step toward a future in which microchips communicate entirely with particle

BC Platforms has been recognized as one of the Top AWS Partners to Watch in 2026 by CIO Times. The following profile, published as part of CIO Times’ Top AWS Partners to Watch in 2026 edition, is reproduced with permission. Healthcare innovation is being reshaped by a critical challenge: organizations have more data than ever, yet much of it remains fragmented, difficult to access, and constrained by governance requirements. BC Platforms helps life sciences, healthcare, and research organization

Neurodegenerative clinical trials present unique challenges that extend beyond scientific and operational complexity. Disease progression, caregiver responsibilities, travel burden, complex assessments, and patient availability can all influence recruitment, retention, and the overall clinical trial experience. As the field continues to advance, incorporating the perspectives of patients and caregivers into clinical development is increasingly important to designing studies that are both scienti

Lund, Sweden — 11 September 2026 — Camurus today announced that the Nomination Committee for the Annual General Meeting (AGM) 2027 consists of the following persons, who together represent about 38 percent of the total number of shares and votes in Camurus based on the last known shareholder information: The Nomination Committee’s proposals will be presented in the Notice to the AGM 2027 and on Camurus’ website, www.camurus.com. Shareholders who wish to submit proposals t

Today, a brief rundown of news involving Karyopharm Therapeutics and Amgen, as well as updates from BridgeBio Oncology Therapeutics, Evommune, Encoded Therapeutics and Schrdinger that you may have missed.Cash-strapped Karyopharm Therapeutics has reached a deal with creditors thatll give the company extra time to make a $15.8 million debt payment that came due on Thursday. According to a regulatory filing, a group of lenders, noteholders and royalty investors will hold off on taking action throug